BiomX Inc. (PHGE)
0.72
-0.00 (-0.06%)
At close: Jan 14, 2025, 3:59 PM
undefined% (undefined)
| Bid | 0.71 |
| Market Cap | 13.10M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.26 |
| PE Ratio (ttm) | -0.22 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.79 |
| Volume | 66,577 |
| Avg. Volume (20D) | 111,454 |
| Open | 0.75 |
| Previous Close | 0.72 |
| Day's Range | 0.72 - 0.77 |
| 52-Week Range | 0.48 - 8.55 |
| Beta | undefined |
About PHGE
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 13, 2019
Employees 58
Stock Exchange AMEX
Ticker Symbol PHGE
Website https://www.biomx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for PHGE stock is "Buy." The 12-month stock price forecast is $13.5, which is an increase of 1773.44% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
5 months ago ·
Source
-11.41%
BiomX shares are trading lower following Q2 financ...
Unlock content with
Pro Subscription
10 months ago ·
Source
+197.84%
BiomX shares are trading higher after the company announced that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics and a concurrent $50 million in financing.
